



NEONATAL MEDICATION GUIDELINE

Dilacaine Eye Drops

Scope (Staff): Nursing, Medical and Pharmacy Staff

Scope (Area): KEMH NICU, PCH NICU, NETS WA

This document should be read in conjunction with the [Disclaimer](#).

Quick Links

[Dose](#)

[Preparation & Administration](#)

[Side Effects & Interactions](#)

[Monitoring](#)

Restrictions

[Formulary: Unrestricted](#)

Description

Mydriatic, anaesthetic eye drop

Presentation

Eye Drop: 1mL

Each 1mL contains

- Phenylephrine HCl 25mg
- Tropicamide 2.5mg
- Proxymetacaine HCl 1.25mg
- Cyclopentolate HCl 2.5mg

Storage

Refrigerate – Do not Freeze
 Discard 24 Hours after Opening

Indication

RetCAM Imaging – examination of the fundus of the eye.
 Laser Eye Therapy- pre-operative care

Contraindications

Nil

Dose**RetCAM Imaging:**

Instil eye drops at least 60 minutes prior to examination.

Instil ONE drop into the eye.

After first drop is instilled, wait 5 minutes before administering the SECOND eye drop.

Laser Therapy:

Instil ONE drop into each eye every 30 minutes for two hours prior to time of surgery

Side Effects

Increased intraocular pressure

May cause vasoconstriction of facial skin

Comments

For individual patient use only

Related Policies, Procedures & Guidelines

[Retinopathy of Prematurity \(ROP\)](#)

References

[Retinopathy of Prematurity \(ROP\) Screening Treatment – Ophthalmology Consultations](#)

Keywords	Dilacaine, RETCAM, ROP				
Document Owner:	Head of Department - Neonatology				
Author/ Reviewer	KEMH & PCH Pharmacy/Neonatology Directorate				
Version Info:	4.0				
Date First Issued:	01/03/2013	Last Reviewed:	27/07/2022	Review Date:	27/07/2025
Endorsed by:	Neonatal Directorate Management Group			Date:	23/08/2022
NSQHS Standards Applicable:	<input checked="" type="checkbox"/>  Std 1: Clinical Governance <input type="checkbox"/>  Std 2: Partnering with Consumers <input type="checkbox"/>  Std 3: Preventing and Controlling Healthcare Associated Infection <input checked="" type="checkbox"/>  Std 4: Medication Safety		<input type="checkbox"/>  Std 5: Comprehensive Care <input type="checkbox"/>  Std 6: Communicating for Safety <input type="checkbox"/>  Std 7: Blood Management <input type="checkbox"/>  Std 8: Recognising and Responding to Acute Deterioration		
Printed or personally saved electronic copies of this document are considered uncontrolled. Access the current version from WNHS HealthPoint.					

The health impact upon Aboriginal people has been considered, and where relevant incorporated and appropriately addressed in the development of this document (insert ISD Number). (Please refer to the Aboriginal Health Impact Statement and Declaration for Department of Health and Health Service Provider Guidelines – please delete once you have completed this).

This document can be made available in alternative formats on request for a person with a disability.

© Women and Newborn Health Service 2020

Copyright of this material is vested in the State of Western Australia unless otherwise indicated. Apart from any fair dealing for the purposes of private study, research, criticism or review, as permitted under the provisions of the Copyright Act 1968, no part may be reproduced or re-used for any purposes whatsoever without written permission of the State of Western Australia.